We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA PANEL TO REVIEW GUIDANT LABELING REQUEST
FDA PANEL TO REVIEW GUIDANT LABELING REQUEST
June 18, 2004
The FDA last week announced that its Circulatory System Devices Panel will review next month Guidant’s submission to expand user labeling, including indications, for its cardiac resynchronization therapy (CRT) defibrillators.